Prismaflex

Prismaflex System

One device for single or multiple organ failure support

One of the world’s most used CRRT devices

When treating critically ill patients, providers need a device they can rely on. For continuous renal replacement therapy (CRRT), the Prismaflex System supports the individual needs of patients with single or multiple organ failure therapies in one device. Prismaflex is a versatile machine with a comprehensive product offering, along with training and support to help deliver optimized outcomes for the ICU.

Compatible Products

Acute Therapy Systems

No two patients are the same

Every patient that comes into the ICU is different, which means therapies need to be individualized to meet complex, specialized and varied patient needs. But meeting the needs for individualized therapies can put pressure on ICU resources.

With Prismaflex, clinicians can choose a single device that provides individualized and effective therapies for patients, which could help simplify the complexities the ICU faces and ease the burden on ICU resources.

The Prismaflex System continues to advance therapy delivery as one of the world’s most used CRRT devices, with thousands of systems installed in over 90 countries.

Prismaflex provides multiple CRRT modes

The Prismaflex System delivers multiple modes of CRRT without the need for additional equipment:

  • Continuous veno-venous hemodiafiltration (CVVHDF)
  • Continuous veno-venous hemodialysis (CVVHD)
  • Continuous veno-venous hemofiltration (CVVH)
  • Slow continuous ultrafiltration (SCUF)1
Healthcare professional interacts with the Prismaflex System

Easing the delivery of multi-organ support

Prismaflex is a versatile, user-friendly system that delivers single or combined intensive care therapies without the need for any additional equipment, offering operational and training efficiencies. Choose from a wide range of filtersets and solutions to fit each patient’s needs:

Oxiris Set

The only 3-in-1 blood purification filterset to effectively  remove inflammatory mediators such as cytokines and endotoxins as a blood purification therapy for sepsis management. Therapy can be delivered as a stand alone hemoperfusion treatment or while delivering CRRT.2

Integrated Citrate and Calcium Management

Fully integrated citrate and calcium management to enable delivery of regional citrate anticoagulation for all CRRT modalities.

AN69ST Membrane

Proprietary membrane that provides a unique combination of diffusion, convection and adsorption functionalities, which is clinically proven to provide removal of middle-size molecules in convective therapies3 or via adsorption.4,5

TPE Sets

Plasma protein removal in both adults and children (≥9 kg) for therapeutic plasma exchange (TPE) blood purification therapy.6

Smooth transition to the PrisMax 2 System

Busy clinicians must limit potential disruptions in workflow and nurse training that can come with switching to a new system. The PrisMax 2 System is built on the workflow Prismaflex users already know and comes with Vantive service, training and support to allow a smooth transition from Prismaflex to PrisMax 2.

  • Familiar therapies and modalities 
  • Continued use of same filtersets and solutions
  • Similar alarm management
Want to take the next step?

Related products

Important Safety Information

PrisMax:

  • The PrisMax control unit is intended for:

Continuous Renal Replacement Therapy (CRRT) for patients with acute renal failure and/or fluid overload.

  • Therapeutic Plasma Exchange (TPE) therapy for patients with diseases where removal of plasma components is indicated.
  • Hemoperfusion (HP) for patients with conditions where immediate removal of substances by adsorption is indicated.

All treatments administered via the PrisMax control unit must be prescribed by a physician.

WARNING!

Use only fluids designed for intravenous operations and are approved for CRRT/TPE/HP usage. Do not use fluids intended for any other usage like enteral feedings/lipids or cytotoxic drugs.

CONTRAINDICATIONS

There are no known absolute contraindications to Continuous Renal Replacement Therapies.

There are no known contraindications to Therapeutic Plasma Exchange.

There are no known contraindications to Hemoperfusion.

Regional Citrate Anticoagulation is contraindicated in patients with severe liver failure and shock with muscle hypoperfusion.

For the following conditions a careful assessment of the individual risk/benefit ratio has to be made by the treating physician (relative contraindications).

  • Inability to establish vascular access.
  • Severe hemodynamic instability.
  • Known hypersensitivity to any component of the Prismaflex disposable set.

 

TPE Sets:

The Prismaflex TPE1000/TPE2000 set is indicated for use only with the PrismaFlex control unit or with the PrisMax control unit (in countries where PrisMax is cleared or registered), after having selected TPE therapy (therapeutic plasma exchange).

The Prismaflex TPE1000/TPE2000 set is intended for use in therapeutic plasma exchange, thus in diseases where removal of plasma components in indicated.

The use of the Prismaflex TPE1000 set should be restricted to patients with a body weight greater than 9kgs (20lbs).

The use of the Prismaflex TPE2000 set should be restricted to adults.

The size, weight, state of uremia, cardiac status and general physical condition of the patient must be evaluated by the prescribing physician before each treatment.

The device should be used only on the direction of a physician who has evaluated all of the pertinent features of this device in relation to the individual patient. Patients with bleeding tendencies must be closely supervised during the treatment.

Treatment should be discontinued if acute hemorrhage that can not be corrected (hematemesis, hemoptysis and melena) occurs during TPE.

All treatments administered via the Prismaflex set must be prescribed by a physician.

 

Oxiris:

Intended Purpose

The oXiris set is a single use device that provides blood purification via diffusion, convection and adsorption through a semipermeable membrane.

The oXiris set is for use only in conjunction with the PrismaFlex control unit or with the PrisMax control unit (in countries where PrisMax is cleared or registered).

All treatments administered with the oXiris set must be prescribed by a physician. The size, weight, state of uremia, cardiac status, and general physical condition of the patient must be carefully evaluated by the prescribing physician before each treatment.

Indications

The oXiris set is indicated for use in critically ill patients with a body weight equal or greater than 30 kg (66lb) for hemoperfusion and / or renal replacement modalities such as:

  • Slow Continuous UltraFiltration (SCUF)
  • Continuous Veno-Venous Hemofiltration (CVVH)
  • Continuous Veno-Venous HemoDialysis (CVVHD)
  • Continuous Veno-Venous HemoDiaFiltration (CVVHDF)

When used for hemoperfusion only, the SCUF mode shall be used with no fluid removal prescription, as the indication is to reduce elevated levels of inflammatory mediators, such as cytokines, and to reduce endotoxins.

If patients suffer from acute kidney injury and / or volume overload, the oXiris set is indicated for continuous renal replacement therapies (CRRT), to perform fluid management and removal of uremic toxins. The removal of inflammatory mediators and endotoxins is performed simultaneously when indicated for CRRT.

Contraindications

It is contraindicated to use the oXiris set where patients present a known allergy to heparin or have type II thrombocytopenia caused by heparin (HIT Syndrome type II).

Any contraindications indicated in the respective Instructions for use of all drugs used simultaneously with this set should be taken into account.

For the following conditions a careful assessment of the individual risk/benefit ratio has to be made by the treating physician (relative contraindications):

  • inability to establish vascular access,
  • severe hemodynamic instability,
  • known hypersensitivity to any component of the oXiris set.

 

PRISMAFLEX

Intended use

The PRISMAFLEX control unit is intended for:

  • Continuous Renal Replacement Therapy for patients with acute renal failure and/or fluid overload.
  • Therapeutic Plasma Exchange Therapy for patients with diseases where removal of plasma components is indicated.
  • Hemoperfusion for patients with conditions where immediate removal of substances by adsorption is indicated.

All treatments administered via the PRISMAFLEX control unit must be prescribed by a physician.

Contraindications

There are no known contraindications to Continuous Renal Replacement Therapies.

There are no known contraindications to Therapeutic Plasma Exchange.

There are no known contraindications to Hemoperfusion.

For contraindications that may apply to the disposable set selected for the therapy, refer to the Instructions For Use of the disposable set.

PRISMAFLEX HAEMODIALYSIS SETS WITH FILTER

Intended Purpose

The Prismaflex ST set is a single use device that provides blood purification through a semipermeable membrane.

The Prismaflex ST set is for use only in conjunction with the PrismaFlex control unit or with the PrisMax control unit (in countries where PrisMax is cleared or registered).

All treatments administered via the Prismaflex set must be prescribed by a physician. The size, weight, state of uremia, cardiac status, and general physical condition of the patient must be carefully evaluated by the prescribing physician before each treatment.

Indications

If patients suffer from acute kidney injury and / or volume overload, the Prismaflex ST set is indicated for continuous renal replacement therapies (CRRT), in modalities such as

  • Slow Continuous UltraFiltration (SCUF)
  • Continuous Veno-Venous Hemofiltration (CVVH)
  • Continuous Veno-Venous HemoDialysis (CVVHD)
  • Continuous Veno-Venous HemoDiaFiltration (CVVHDF) to perform fluid management and reduction of uremic toxins.

The Prismaflex ST100 and ST150 set is indicated for use in patients with a body weight equal or greater than 30 kg (66lb) and Prismaflex ST60 set is indicated to patients with a body weight greater than 11kg (24lb).

Contraindications

There are no known absolute contraindications to continuous renal replacement therapies. For the following conditions a careful assessment of the individual risk/benefit ratio has to be made by the treating physician (relative contraindications):

  • inability to establish vascular access,
  • severe hemodynamic instability,
  • known hypersensitivity to any component of the Prismaflex set.

 

PrisMax

CE 0123

 

Prismaflex/TherMax/Oxiris/TPE Sets

CE 2797

 

Vantive, AN69ST, GamCath, Oxiris, Prismaflex, PrisMax and TherMax are trademarks of Vantive Health LLC or its affiliates.

References

  1. Baxter International Inc. Prismaflex Operator’s Manual. Version 8.XX. Deerfield (IL): Baxter Healthcare Corporation; 2015.

  2. Vantive Health LLC. Oxiris Brochure. 2025. Internal Documentation.

  3. Troyanov S, Cardinal J, Geadah D, et al. Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multilflow-100 and HF1000 filters. Nephrol Dial Transplant. 2003;18:961–966.

  4. Thomas M, Moriyama K, Ledebo I. Evolution of the world's first high permeability membrane. Contrib Nephrol. 2011;173:119-129.

  5. Quinto BMR, Lizuka IJ, Monte JCM, et al. TNF-α depuration is a predictor of mortality in critically ill patients under continuous veno-venous hemodiafiltration treatment. Cytokine. 2015;71(2):255-260.

  6. Vantive Health LLC. TPE 1000 / TPE 2000 Specification Sheet. 2025. Internal Documentation.